Research Use Only (RUO) Nucleic Acid Extraction Reagents & Kits

The category is centered on RUO products, and the FFPE RNA and cfDNA kits are explicitly designated Research Use Only. That means they are intended for laboratory research workflows and not for diagnostic or clinical use without additional validation. Some related Cambrian workflows mention clinical laboratory use, so buyers should confirm the exact regulatory status of each kit before selection.

These kits support a broad range of downstream workflows, including RNA-seq, transcriptome analysis, gene expression profiling, NGS library preparation, PCR, qPCR, digital PCR, mutation analysis, biomarker discovery, liquid biopsy assay development, and fusion gene detection. Product-specific performance claims include high-integrity FFPE RNA, selective recovery of 150–200 bp cfDNA fragments, and high-molecular-weight gDNA for sequencing and molecular analysis.

Yes. Automation compatibility is a recurring strength across the category. Multiple kits are designed for use with Cambrian Bioworks' Manta platform, and several products use cartridge-based or automation-friendly magnetic bead workflows. This helps laboratories reduce hands-on time, improve reproducibility, and run flexible sample volumes or throughput without the batching pressure common in manual extraction methods.

Workflow times vary by kit and sample type, but speed is a clear category advantage. FFPE RNA and FFPE gDNA workflows list 28-minute processing after lysis, whole blood gDNA runs in under 30 minutes, whole blood RNA has a 50-minute on-deck time, and the cfDNA kit completes extraction in about 55 minutes. These timelines support same-day research workflows and higher lab throughput.

Several products are specifically optimized for oncology workflows. The cfDNA kit preferentially captures 150–200 bp tumor-derived fragments and is positioned for ctDNA analysis, MRD detection, and treatment monitoring. The FFPE RNA and gDNA kits support tumor profiling, biomarker studies, fusion detection, and retrospective clinical research using archived tissue, making them well aligned with translational oncology programs.

Selection should start with sample type and downstream assay. Choose FFPE RNA for transcriptomics and expression studies from archived tissue, plasma cfDNA for liquid biopsy and ctDNA-focused workflows, whole blood RNA for transcriptome and expression analysis, and gDNA kits for PCR, NGS, mutation analysis, or genetic testing. Input volume, processing time, automation needs, and contamination control are also important comparison points.